Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 7.975p 7.70p 8.25p 7.975p 7.975p 7.975p 15,953 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -0.5 -0.2 - 17

Eden Research Share Discussion Threads

Showing 6851 to 6873 of 8150 messages
Chat Pages: Latest  278  277  276  275  274  273  272  271  270  269  268  267  Older
DateSubjectAuthorDiscuss
27/4/2019
14:46
Again..looking at the sentence below, I'm trying to fathom what it says about the status of other comparable Nematicides in the EU. I assume all EU countries will have had previous access to Nematicides so does this statement acknowledge that all other similar application Nematicides are unsuitable? If so surely all other countries will wish to enact 'emergency authorisations' in the absence of 'suitable commercially-available alternatives'. This suggests to me Italy will not be alone and also means, does it not that Eden have this niche market all to themselves? Italy grants "emergency use" Cedroz authorisation Such "emergency" authorisations are allowed by EU member states when local regulatory authorities judge that they are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives
supersonico
27/4/2019
10:29
Hi AttyG,You could obviously tell I know little about how options work and I thank you for giving me this information.I too hope that they make many millions and that the company pays a healthy dividend.I'd like to see the share price into the pounds, but not just yet. They are cheap to buy just now and I'm still accumulating.
wilmer100
27/4/2019
09:59
Could the other platform be related to the Anti-microbial component that Xinova refer to?
supersonico
27/4/2019
09:46
Hi Wilmer, They will be granted if share price conditions are met in Sept 2019 and 2020. Sean and Alex have a period of time in which to excercise them - from my understanding, as soon as any awarded option is taken up a tax charge will be crystallised (benefit in kind). Such a tax charge may necessitate Sean and or Alex to then sell a quantity of the shares awarded to meet said tax bill. It therefore makes sense not to excercise the award till the last possible date or if they believe the share price has become too toppy and they want to cash in. I am hoping they receive the awards and that they make several millions. My understanding is the sustaine tech is developed by/from/in collaboration with the US uni. Investing raises an intriguing point - if there is another platform to Eden's IP, then it would be good if this was made clear. I am delighted with the granting of the emergency use of Cedroz in Italy. Fingers crossed this means they will get on with providing full continuing use approval in short order. Perhaps we may enjoy more such RNSs in the near future. For me this is a fundamental change in the commercial outlook for Eden - for the better, in case someone doubts the view of a deluded bull!
attyg
27/4/2019
09:37
Mevalone/ Cedroz Italy Approval time Comparison Mevalone EU Product Authorisation 26th May 2015 Approval of 3AEY in Italy 11th Feb 2016 Roughly +/- 9 months Cedroz EU Product Authorisation - Cedroz 20th Feb 2019 Italy grants "emergency use" Cedroz authorisation 26th Apr 2019 Roughly +/- 2 months
supersonico
27/4/2019
09:03
OK. Thanks, as I said my knowledge is not perfect.2027 does seem a long time from now. I'm in this for the long term if possible and have a fantasy that the dividend could be greater than the present share price.Over 5 years invested in this company and still building my share holding.
wilmer100
27/4/2019
08:38
WILMER100 said "I thought 2 million of the options expired September 2019 and a further 2 million September 2020". Those are separate options
investingisatrickygame
27/4/2019
07:14
I thought 2 million of the options expired September 2019 and a further 2 million September 2020.Also I can't see it on their website but I do believe that the 2nd technology platform was obtained from the university of Massachusetts.I could be wrong, my knowledge is not perfect.
wilmer100
27/4/2019
00:14
Printed copy of the 2018 Annual Report I ordered and received a copy today. Firstly, for anyone that doesn't have a copy, I would recommend you get one. It is comprehensive and beautifully presented, in fact an excellent document in print to go to any potential investor and far more impactful than an online PDF version. I have noticed a few interesting things though (not all new) 1) Eden seeks to be the leader in sustainable bioactive products enabled or enhanced by Sustaine. As another poster has mentioned, I would expect Sustaine to be of greater value than developing a long line of bioactive products, but clearly Eden is intent on building a strong product portfolio 2) Eden's proven addressable market is $1.2 billion today, tomorrow it grows to $4 billion not including Sustaine related products. $4 billion is $2 billion bigger than quoted at the Proactive presentation on the 12th February 2019. Slide 18 hxxp://www.edenresearch.com/~/media/Files/E/Eden-Research/documents/reports-and-presentation/eden-presentation-feb-19-proactive.pdf 3) Page 11 of the printed report "Eden is leveraging two technology platforms to provide sustainable solutions". What is the second technology platform as I only know of one.....Sustaine! 4) Sustaine is being tested by some of the major agchem companies. Would it be possible to know who they are as Sipcam is not one of them in my opinion. Bayer is likely one, who are the others? 5) Pages 14 & 15, shareholder engagement. Eden details an "Investor Relations Calendar (typical, rolling)". Aside of the AGM, it is heavily focused towards the City in my opinion. They do say the AGM's are generally well attended. I guess, to be fair, that is subjective, but I wouldn't agree with that given the size of the share register. 6) Sean and Alex between them have 4 million, nil value options expiring 2027, so time really is on their side! 7) For 'Super', page 29, the Bank of New York (nominees) holds 3.37% of the issued share capital 8) Page 3, "our Commercial Partners" continues to position Bayer first, even after many, many, years of delays. Relevant or not? Accepting that it will cost a few quid in printing, it really is well presented and I would be handing it out to every potential interested party. It's a shame that it can't go to every one of our 2,000 registered shareholders as I think it would be reinvigorating for many.
investingisatrickygame
26/4/2019
19:03
I was told this at 10.20am this morning that MM were bidding for 1m shares at 11p. That bid for there for only 15min. Not sure if the particular MM did manage to acquire the shares for his clients. very interesting development.
northwick
26/4/2019
15:06
Brucie5.. Your not the only one. Commiserations to those reading this BB who know this marks an end to their BS commentary. LOL Their will be no Eulogy.
supersonico
26/4/2019
15:05
The Italian local regulatory authorities have judged that "emergency" authorisations are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives. The words "lack of suitable competition" and "open door" spring to mind for Cedroz take-up in Italy. The local regulatory authorities are obviously well informed regarding Cedroz.
weyweyumfozo
26/4/2019
14:58
Yes, indeed, Wan, and brings forward the likelihood of additional income stream for 2019!
brucie5
26/4/2019
14:51
Well, am I the only one to find today's RNS even vaguely exciting? Eastman is really working hard for us, it seems. They seem to have impressed the Italians, who have a huge agricultural sector; never mind the fact that Italy, as the world's largest wine producer is already using Mevalone via Sipcam.
brucie5
26/4/2019
14:43
Super, Your post above is right in that the statement you re-quote should not be underestimated. It is quite a statement and Eden should look to capitalise on the same. However,...… ipeesquint is right in my book about the jam tomorrow, inappropriate and disproportionate pay rises, bonuses and share options that have been awarded. This doesn't say 'we are in it together or our interests are aligned with yours' because they're simply not when the share price is 3 years static and illiquid. That really is a statement suggesting Cedroz is about to grab immediate and significant market share straight out the gate in Italy. Investors are right to be weary with Eden and they will look to exit as soon as. New investors are right to be wary of Eden until delivery changes. I love the Eden story, but I too am getting tired of it. I would love it again though if Eden would drive their share price to many multiples of today's price, today and then we can start to look forward to the forward journey again. The share price is the biggest elephant in the room. So I am all for the pay rises, bonuses and share options, with the former two coming when Eden's share price is north of 30p and the latter exercisable when the shares are 40-50p
investingisatrickygame
26/4/2019
14:28
Ipeesquint, The words of Zach Bush..Autism rates have doubled in the last 6 years to 1 in every 30 kids and by 2030/5 based on current projections 1 in 3 children will be diagnosed as being on the Autistic spectrum. 46% of children have a chronic Health issue. These are end of Empire numbers. @13min hTTps://www.youtube.com/watch?v=X3aOQ0N74PI&fbclid=IwAR08MulF_LQ5oC8iOFsSD_7Nl4F0arIVQVo0s7ewgRlHwardxQCFgnusiys With these sorts of stats routinely thrown around and bio technology rapidly evolving I think were all frustrated. That may well be down to management but I lean more towards NDA's and evolving product development as a reason why were still waiting. The statement we all read today, below, should not be underestimated imo as not only does it show a vacuum in the Green revolution technology, it marks a step change in the leverage our partners have and their confidence that the product performs better than conventional chemistry. It shows the confidence and trust regulators are gaining for Eden technology. It also marks the acceptance and maturity of Eden's tech reputation for Biopesticide products that was not their or was more cautious with Mevalone. As we have all grumbled about the slow progress of the share price the Times have changed before our eyes. The tide is turning in Eden's favour, but not many realise it right now.. but they will. 'Such emergency authorisations are allowed by EU member states when local regulatory authorities judge that they are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives'.
supersonico
26/4/2019
13:56
Investing all true what your saying. I don’t post often as I am a bit weary of Eden having owned quite a pile for so long. I hope one day to get a bit of that future jam but suspect my kids are more likely to benefit when I am gone. It is my worst ever investment and while I still have hope .....it diminishes every time Sean awards an inappropriate and disproportionate pay rise to him and Alex. The AGM used to be an exciting time but of late I find myself bashing my teeth at what comes out of it. Groaning is also a firm favourite and a requirement for a long time holder of which there are surprisingly many. I’m not sure what keeps us here anymore. Good luck all.
ipeesquint
26/4/2019
12:03
Dave Goulson talks about the causes of insect declines, and how we might all help to reverse them (only the short intro is in German!): hTTps://www.youtube.com/watch?v=JZYWYK4GbAo&list=PLP4P7rl8GkSdcrwFOsvO4shVVxlERLXK0&index=5&t=0s …………….. hTTps://www.youtube.com/watch?time_continue=41&v=u_o7FNkjzb0
supersonico
26/4/2019
10:15
Le cognac Hennessy veut bannir les herbicides d’ici 2028 hTTp://www.terredevins.com/actualites/le-cognac-hennessy-veut-bannir-les-herbicides-dici-2028/ The Hennessy cognac house intends to ban herbicides vines of its 1,600 winemakers partners by 2028 by proposing a technical and financial support plan, we learned Thursday from the world number one. The CEO of the group, Bernard Peillon, made this announcement Wednesday night, during the meeting partners in Cognac, with independent winemakers who exploit 32,000 hectares on behalf of Hennessy on a total of 76,000 ha for the appellation in Charente and Charente -Maritime, according to its communication department. According to the calendar unveiled at this annual meeting, winemakers delivering to Hennessy will have to engage in an environmental certification process within three years and obtain in 2025 the "High environmental value" (HVE) label, which imposes the need to protect the environment. plant and animal biodiversity and limited treatments. In nine years, Hennessy's partner vineyards will no longer need to use any herbicide. To get rid of glyphosate, flazasulfuron and other weed killers, Hennessy, which belongs to the luxury giant LVMH, has carried out conclusive tests on its 180 ha vineyard. In the coming weeks, he intends to present his technical and financial assistance plan to assist winemakers with this change in practices. The alternatives to herbicides retained are mainly mechanical but also vegetable. Robots, pressurized water or tea-based porridge could be used in the vineyards. At the cognac appellation level, two agri-environmental measures were recently included in the specifications to limit the use of chemical weed control, with the goal by 2025 of reducing the use of herbicides by 50%.
supersonico
26/4/2019
09:14
Shareholder revolt on ss and aa remuneration and the whole pay committee setup... tied in with share price appreciation and commercial success?? I would vote for that so this jam tomorrow story might bare fruit before they retire... grrrh it's beyond excessive their pay rises given the depreciating share price...
bjlk
26/4/2019
08:38
Different sort of 'emergency' I believe Monet. Use on Kiwi is More like a derogation as already approved Mevalone gets with Pomegranates. This is an 'emergency' cart as the 'urgent need' has come prior to the 'approval' paperwork horse in changing times.
supersonico
26/4/2019
08:24
Why didn't we get a RNS for this? 3LOGY: authorized for use in plant health emergency From 8 April it will be possible to use 3LOGY for Actinidia botrytis The botrytis ( Botrytis cinerea or gray mold), is a pathogen that causes severe changes in load of flowers, fruits, leaves and shoots of numerous crops The Botrytis on kiwifruit (or kiwi) manifests itself already in the early stages of flowering, growing in flowers with brownish rots that induce abundant drops and prevent normal fruit set. The fungus can also remain latent and subsequently cause serious damage to fruits that deteriorate to such an extent that they can no longer be sold. Botrytis develops especially in particularly wet years, Favored by heavy rains and repeated 3LOGY , innovative antibotritico based on terpenes, was authorized for a period of 120 days, from 8 April to August 5, for danger to plant health on botrytis Actinidia hTTp://www.sipcamitalia.it/it/news/12/3logy-autorizzato-l-impiego-per-emergenza-fitosanitaria/153_NC
monet
26/4/2019
08:16
It can be all summed up by Edenberg , NDA's , Incongruence, technical issues and Scandi Noir imo at the S curve mathematical collapse of the Green Revolution narrative. The 'Emergency' status tells those who follow the non 'effective' 'Direction of Travel news' everything we knew already and will be repeated across the board imo.
supersonico
Chat Pages: Latest  278  277  276  275  274  273  272  271  270  269  268  267  Older
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191014 20:20:55